Sorry, you need to enable JavaScript to visit this website.

Understanding Multiple Myeloma

PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA HAVE A CRITICAL NEED FOR ADDITIONAL THERAPEUTIC APPROACHES1-3

Multiple myeloma is incurable, and patients can eventually become refractory to multiple classes of treatment

Proteasome inhibitor icon Proteasome inhibitors
Proteasome inhibitor icon Immunomodulatory agents
Blue monoclonal antibody icon Anti-CD38 monoclonal antibodies

Patients with triple-class refractory multiple myeloma can have more progressive disease, poor prognosis, and few treatment options remaining.

Patients can continue to progress and require additional therapies.1,3,4

CD38, cluster of differentiation 38.

References:

  1. Mikhael J. Treatment options for triple-class refractory multiple myeloma. Clin Lymphoma Myeloma Leuk. 2020;20(1):1-7.
  2. Bruno AS, Willson JL, Opalinska JM, et al. Recent real-world treatment patterns and outcomes in US patients with relapsed/refractory multiple myeloma. Expert Rev Hematol. 2020;13(9):1017-1025.
  3. Sonneveld P, Broijl A. Treatment of relapsed and refractory multiple myeloma. Haematologica. 2016;101(4):396-406.
  4. Yong K, Delforge M, Driessen C, et al. Multiple myeloma: patient outcomes in real-world practice. Br J Haematol. 2016;175(2):252-264.

Yellow monoclonal antibody iconDiscover a unique mechanism of actionArrow icon

Email iconConnect with a Janssen Oncology representativeTalk with Us
Stacked books iconAccess resources to help patients receive TECVAYLI® Explore Resources